Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases

BMC Research Notes

Haruki Kume²  Junzo Tomoishi¹  Kenji Yoda¹  Katsuhiro Makino¹ 

[1] Department of Urology, Ome Municipal General Hospital, 4-16-5 Higashiome, Ome, Tokyo, Japan;Department of Urology, The University of Tokyo, Tokyo, Japan

关键词: Tyrosine kinase inhibitors;    Treatment toxicity;    Renal cancer medical treatment;    Metastatic renal cell carcinoma;    Sunitinib;   

Others  :  1098204
DOI  :  10.1186/1756-0500-7-872

 received in 2014-01-08, accepted in 2014-11-25,  发布年份 2014

【 摘 要 】

Background

Sunitinib, an oral multitarget tyrosine kinase inhibitor and standard first-line treatment for metastatic renal cell carcinoma (mRCC), is generally administered on a 6-week schedule (4 weeks on/2 weeks off). However, drug toxicity often leads to temporary treatment interruption, resulting in reduced treatment efficacy. In this report, we investigated whether sunitinib administration of at a dose of 25 mg/day in a 2-weeks-on/1-week-off cycle would reduce the incidence of drug-related side effects while maintaining drug efficacy.

Findings

A total of six patients with mRCC were orally administered sunitinib at a dose of 25 mg/day in a 2-weeks-on/1-week-off regimen until intolerable toxicities occurred. All enrolled patients were assessed for toxicity and response. The median treatment period was 24 months (range, 9–40 months). Objective responses were as follows: disease stabilization of >6 months was achieved in all patients. The most important toxicities were neutropenia, fatigue, and proteinuria, but all were controlled.

Conclusions

Oral sunitinib at 25 mg/day in a 2-weeks-on/1-week-off regimen to Japanese patients can avoid drug-related toxicities while achieving the same dose intensity as a 6-week schedule. Because these data were derived from a small number of patients, future prospective studies of modified sunitinib administration schedules are warranted.

【 授权许可】

   
2014 Makino et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 1996, 335:865-875.
• [2]Vogelzang NJ, Lipton A, Figlin RA: Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol 1993, 11:1809-1816.
• [3]Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J Urol 2000, 163:408-417.
• [4]Wirth MP: Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 1993, 20:283-295.
• [5]Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003, 2:471-478.
• [6]O’Farrell A-M, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KWH, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101:3597-3605.
• [7]Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327-337.
• [8]Neri B, Vannini A, Brugia M, Muto A, Rangan S, Rediti M, Tassi R, Cerullo C: Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients. Int J Urol 2013, 20:478-483.
• [9]Neri B, Vannini A, Tassi R, Brugia M, Rangan S, Rediti M, Cerullo C: The efficacy and tolerability of a sunitinib 3-week administration schedule in metastatic renal cell carcinoma patients: report of three cases. Oncol Res 2012, 20:259-264.
• [10]Hutson TE, Figlin RA, Kuhn JG, Motzer RJ: Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008, 13:1084-1096.
• [11]Suarez C, Rini BI: Determining the optimal dose and schedule of sunitinib: some answers, more questions. Cancer 2012, 118:1178-1180.
• [12]Barrios CH, Hernandez-Barajas D, Brown MP, Lee S-H, Fein L, Liu J-H, Hariharan S, Martell BA, Yuan J, Bello A, Wang Z, Mundayat R, Rha S-Y: Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 2012, 118:1252-1259.